Medical decision analysis of chemoprevention against esophageal adenocarcinoma

Gastroenterology

Volumn 124, Issue 7, 2003, Pages 1758-1766

  Sonnenberg, Amnon ^a,b   Fennerty, M Brian ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADENOCARCINOMA; ADULT; ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER RISK; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DYSPLASIA; ENDOSCOPY; ESOPHAGUS CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME;

EID: 0038281538     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00393-7     Document Type: Article

References (33)

1. Fennerty MB. Barrett's-related esophageal cancer: has the final hurdle been cleared, now paving the way for human chemoprevention trials? Gastroenterology 2002;122:1172-1175.
2. Gupta RA, DuBois RN. Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus. J Natl Cancer Inst 2002;94:406-407.
3. Thun MJ, Namboodiri MM, Calle EE. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-1327.
4. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal cancer. Cancer 1995;76:1116-1119.
5. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF Jr, Blot WJ. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
6. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: casecontrol study in general practice research database. BMJ 2000; 320:1642-1646.
7. Kune GA, Kune S, Watson FL. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne colorectal cancer study. Cancer Res 1988;48: 4399-4404.
8. Müller AD, Sonnenberg A, Wasserman IH. Diseases preceding colon cancer: a case-control study among veterans. Dig Dis Sci 1994;39:2480-2484.
9. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-614.
10. DuBois RN, Giardiello FM, Smalley WE. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 1996;25:773-791.
11. Wilson KT, Fu S, Kanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinoma. Cancer Res 1998;58:2929-2934.
12. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase-2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118:487-496.
13. Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002;123:60-67.
14. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS, Burgart LJ. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002; 122:1101-1112.
15. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:332-338.
16. Sonnenberg A, Soni A, Sampliner RE. Medical decision analysis of endoscopic surveillance of Barrett's esophagus to prevent esophageal adenocarcinoma. Aliment Pharmacol Ther 2002;16: 41-50.
17. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk of Barrett's esophagus? Gastroenterology 2000;119:333-338.
18. Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988;75:760-763.
19. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-1256.
20. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:1888-1893.
21. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, Seidel UJ, Sonnenberg A. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120:1607-1619.
22. National Center for Health Statistics. US decennial life tables for 1989-91. DHHS publication no. PHS-98-1150-1. Volume 1, no. 1. Hyattsville, MD: 1997.
23. Sampliner RE. Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97:1888-1894.
24. Soni A, Sonnenberg A. Healthcare resource utilization in the management of oesophageal adenocarcinoma. Aliment Pharmacol Ther 2001;15:945-951.
25. Smalley WE, Griffin MR, Fought RL, Ray WA. Excess cost from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996;11:461-469.
26. Weinstein MC, Stason WB. Foundations of cost-effectiveness for health and medical practices. N Engl J Med 1977;296:716-721.
27. Siegel JE, Weinstein MC, Torrance GW. Reporting cost-effectiveness studies and results, In: Gold MR, Siegel JE, Russel LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford, 1996:276-303.
28. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press, 1997:96-138, 268-272.
29. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol 2000;27:2203-2214.
30. Iso H, Hennekens CH, Stampfer MJ, Rexrode KM, Colditz GA, Speizer FE, Willett WC, Manson JE. Prospective study of aspirin use and risk of stroke in women. Stroke 1999;30:1764-1771.
31. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke 1996; 27:1459-1466.
32. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 2002;287:1972-1981.
33. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123:461-467.